Tharimmune, Inc. announced on September 30, 2024, that it has entered into a nonbinding, exclusive letter of intent (LOI) to acquire all outstanding shares of privately-held Intract Pharma Ltd. The acquisition is planned in exchange for newly issued restricted common stock of Tharimmune.
This business combination aims to form a best-in-class, transformative oral biologics company. The strategic rationale includes leveraging synergies between Tharimmune's clinical-stage assets and Intract's disruptive delivery platform for oral biologics to drive pipeline growth.
The merger is anticipated to close in the first quarter of 2025. This move positions Tharimmune to potentially revolutionize the treatment of inflammatory conditions by offering non-injectable biologic therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.